Carboplatin
别名: NSC 241240, JM-8, CBDCA 中文名称：卡铂
铂类药物不建议使用DMSO溶解，易失活！
Carboplatin是 CDDP 的衍生物，是一种 DNA 合成抑制剂，在 A2780、SKOV-3、IGROV-1 和 HX62 细胞中可与 DNA 结合，抑制复制和转录，诱导细胞死亡并干扰细胞的修复机制发挥作用 。 它诱导 DNA 链间交联和 DNA-蛋白质交联的形成。在溶液中不稳定，请现配现用！铂类药物不建议用DMSO溶解，易失活！
Carboplatin Chemical Structure
CAS: 41575-94-4
客户使用Selleck的Carboplatin发表文献117篇
产品质控
Carboplatin相关产品
| 相关化合物库 | FDA药物库 天然产物库 凋亡分子化合物库 DNA损伤/ DNA修复化合物库 细胞周期化合物库 | 点击展开 |
|---|
Antineoplastic and Immunosuppressive Antibiotics抑制剂选择性比较
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| H460 | Growth Inhibition Assay | 7.9 μM | 24 h | shows a radiosensitizing effect to X-rays | 25599995 |
| A549/CDDP | Growth Inhibition Assay | 0.2-4000 μM | 72 h | IC50=240 ± 45.7 μM | 25625243 |
| A549 | Growth Inhibition Assay | 0.2-4000 μM | 72 h | IC50=126 ± 5.0 μM | 25625243 |
| A-549 | Fuction Assay | 0.5 μM | 48 h | inhibits of cell migration | 25755690 |
| A-549 | Fuction Assay | 0.5 μM | 48 h | shows aberrant microtubule disruption | 25755690 |
| A-549 | Apoptosis Assay | 0.5 μM | 48 h | shows early apoptosis features including blebbing and chromatin condensation | 25755690 |
| A-549 | Growth Inhibition Assay | 0.5 μM | 24 h | inhibits cell growth significantly | 25755690 |
| MCF7 | Growth Inhibition Assay | 20 μM | 72 h | induces cell death of HP1β-depleted MCF7 cells | 25769025 |
| T47D | Growth Inhibition Assay | 0-220 μg/ml | 72 h | IC50 = 48.9 μM | 25837691 |
| MDA-MB-231 | Growth Inhibition Assay | 0-220 μg/ml | 72 h | IC50 = 86 μM | 25837691 |
| H1975 | Growth Inhibition Assay | 25 μM | 24 h | inhibits cell growth | 25917317 |
| A549 | Growth Inhibition Assay | 25 μM | 24 h | inhibits cell growth | 25917317 |
| H1975 | Fuction Assay | 0/25/50 μM | 24 h | upregulates miR-218 expression | 25917317 |
| A549 | Fuction Assay | 0/25/50 μM | 24 h | upregulates miR-218 expression | 25917317 |
| H1975 | Fuction Assay | 0/25/50 μM | 24 h | downregulates miR-205 expression | 25917317 |
| A549 | Fuction Assay | 0/25/50 μM | 24 h | downregulates miR-205 expression | 25917317 |
| SKOV3 | Apoptosis Assay | 2 μg/ml | 48 h | induces apoptosis | 26125273 |
| SKOV3 | Growth Inhibition Assay | 0-4 μg/ml | 24/48/72 h | inhibits cell viability dose and time dependently | 26125273 |
| SKOV3 | Growth Inhibition Assay | 60 mg/ml | 1-5 d | inhibits cell viability time dependently | 26137043 |
| Tca8113/PYM | Growth Inhibition Assay | 2-25 μM | 72 h | inhibits cell viability dose dependently | 26137105 |
| Tca8113/CBP | Growth Inhibition Assay | 2-25 μM | 72 h | inhibits cell viability dose dependently | 26137105 |
| Tca8113/ut | Growth Inhibition Assay | 2-25 μM | 72 h | inhibits cell viability dose dependently | 26137105 |
| PC9 | Apoptosis Assay | 100 µM | 72 h | induces apoptosis | 24618809 |
| A549 | Apoptosis Assay | 100 µM | 72 h | induces apoptosis | 24618809 |
| IMR-32 | Fuction Assay | 10 μM | induces apoptosis significantly combined with GSK2830371 | 25658463 | |
| CHP-134 | Fuction Assay | 10 μM | induces apoptosis significantly combined with GSK2830371 | 25658463 | |
| IMR-32 | Growth Inhibition Assay | 1 μM | inhibits significant cell growth combined with GSK2830371 | 25658463 | |
| CHP-134 | Growth Inhibition Assay | 1 μM | inhibits significant cell growth combined with GSK2830371 | 25658463 | |
| OSA | Clonogenic Assay | 2.5/5 μM | results in lower colony formation as compared to either BMI1 siRNA treatment | 26110620 | |
| HeLa | Growth Inhibition Assay | 5-80 μM | inhibits cell growth dose dependently | 25109360 | |
| MCF-7 | Growth Inhibition Assay | 5-80 μM | inhibits cell growth dose dependently | 25109360 | |
| MDA-MB-231 | Growth Inhibition Assay | 5-80 μM | inhibits cell growth dose dependently | 25109360 | |
| OVCAR-3 | Growth Inhibition Assay | 72 h | IC50=32.6 μM | 25520132 | |
| SW626 | Growth Inhibition Assay | 72 h | IC50=97.0 μM | 25520132 | |
| A2780 | Growth Inhibition Assay | 72 h | IC50=145.7 μM | 25520132 | |
| 3AO | Growth Inhibition Assay | 72 h | IC50=63.4 μM | 25520132 | |
| OVCAR-8 | Growth Inhibition Assay | 72 h | IC50=96.0 μM | 25520132 | |
| ES-2 | Growth Inhibition Assay | 72 h | IC50=14.6 μM | 25520132 | |
| SK-OV-3 | Growth Inhibition Assay | 72 h | IC50=104.8 μM | 25520132 | |
| RGE | Growth Inhibition Assay | 72 h | IC80=63 ± 7.4 μM | 25565603 | |
| NRK-52E | Growth Inhibition Assay | 72 h | IC80=179 ± 9.5 μM | 25565603 | |
| RGE | Growth Inhibition Assay | 72 h | IC50=22 ± 7.4 μM | 25565603 | |
| NRK-52E | Growth Inhibition Assay | 72 h | IC50=100 ± 12.9 μM | 25565603 | |
| H460 | Growth Inhibition Assay | 24 h | IC50=7.9 μM | 25599995 | |
| CaOV3 | Growth Inhibition Assay | 72 h | IC50=86.1 μM | 25068849 | |
| OVCAR-3 | Growth Inhibition Assay | 72 h | IC50=179.5 μM | 25068849 | |
| OVCAR-5 | Growth Inhibition Assay | 72 h | IC50=75.7 μM | 25068849 | |
| SKOV-3 | Growth Inhibition Assay | 72 h | IC50=504 μM | 25068849 | |
| OVCAR-4 | Growth Inhibition Assay | 72 h | IC50=290.6 μM | 25068849 | |
| OVCAR-8 | Growth Inhibition Assay | 72 h | IC50=690.2 μM | 25068849 | |
| MA148 | Growth Inhibition Assay | 24 h | IC50=83.6 ± 1.4 μg/ml | 24831091 | |
| A549 | Growth Inhibition Assay | 24 h | IC50=776.0 ± 1.9 μg/ml | 24831091 | |
| MDA-MB-231 | Growth Inhibition Assay | 24 h | IC50=748.0 ± 1.1 μg/ml | 24831091 | |
| NCI-ADR/RES | Growth Inhibition Assay | 24 h | IC50=1753.0 ± 4.4 μg/ml | 24831091 | |
| MA148 | Growth Inhibition Assay | 48 h | IC50=28.1 ± 1.0 μg/ml | 24831091 | |
| A549 | Growth Inhibition Assay | 48 h | IC50=118.0 ± 1.2 μg/ml | 24831091 | |
| MDA-MB-231 | Growth Inhibition Assay | 48 h | IC50=183.0 ± 1.2 μg/ml | 24831091 | |
| NCI-ADR/RES | Growth Inhibition Assay | 48 h | IC50=193.0 ± 1.9 μg/ml | 24831091 | |
| MA148 | Growth Inhibition Assay | 72 h | IC50=13.7 ± 1.2 μg/ml | 24831091 | |
| A549 | Growth Inhibition Assay | 72 h | IC50=64.3 ± 1.1 μg/ml | 24831091 | |
| MDA-MB-231 | Growth Inhibition Assay | 72 h | IC50=99.5 ± 1.1 μg/ml | 24831091 | |
| NCI-ADR/RES | Growth Inhibition Assay | 72 h | IC50=37.4 ± 1.7 μg/ml | 24831091 | |
| A549 | Growth Inhibition Assay | 72 h | IC50=152.409 μM | 24721323 | |
| NCI-H157 | Growth Inhibition Assay | 72 h | IC50=89.977 μM | 24721323 | |
| PC9 | Growth Inhibition Assay | 72 h | GC50=71.6±9.5 µM | 24618809 | |
| A549 | Growth Inhibition Assay | 72 h | GC50=136±31.6 µM | 24618809 | |
| A549 | Growth Inhibition Assay | 24 h | IC10=1.476 nM | 24396437 | |
| H1299 | Growth Inhibition Assay | 24 h | IC10=0.443 nM | 24396437 | |
| HCC15 | Growth Inhibition Assay | 24 h | IC10=0.346 nM | 24396437 | |
| H157 | Growth Inhibition Assay | 24 h | IC10=0.81 nM | 24396437 | |
| 4T1 | Growth Inhibition Assay | IC50=84.62 ± 30.05 μM μM | 25277461 | ||
| A549 | Growth Inhibition Assay | IC50=151.56 ± 53.06 μM | 25277461 | ||
| FN-RMG-1-hFUT | Growth Inhibition Assay | IC50=118.8 ± 13.8 mg/L | 25726913 | ||
| RMG-1-hFUT | Growth Inhibition Assay | IC50=58.1 ± 2.4 mg/L | 25726913 | ||
| FN-RMG-1 | Growth Inhibition Assay | IC50=40.5 ± 4.2 mg/L μM | 25726913 | ||
| RMG-1 | Growth Inhibition Assay | IC50=28.8 ± 3.6 mg/L | 25726913 | ||
| MonoTCC | Growth Inhibition Assay | IC50=5.6 µM | 25773167 | ||
| MegTCC | Growth Inhibition Assay | IC50=4.1 µM | 25773167 | ||
| MCTCC | Growth Inhibition Assay | IC50=2.8 µM | 25773167 | ||
| LCTCC | Growth Inhibition Assay | IC50=3.8 µM | 25773167 | ||
| BALB/3T3 | Growth Inhibition Assay | IC50=14.30 ± 6.68 μM | 25277461 | ||
| B16 | Growth Inhibition Assay | IC50=64.30 ± 6.81 μM | 25277461 | ||
| DU 145 | Growth Inhibition Assay | IC50=35.04 ± 17.54 μM | 25277461 | ||
| FaDu | Growth Inhibition Assay | IC50=45.39 ± 11.50 μM | 25277461 | ||
| HCV-29T | Growth Inhibition Assay | IC50=48.57 ± 22.49 μM | 25277461 | ||
| HL-60 | Growth Inhibition Assay | IC50=11.10 ± 4.47 μM | 25277461 | ||
| HT-29 | Growth Inhibition Assay | IC50=89.16 ± 18.86 μM | 25277461 | ||
| H146 | Growth Inhibition Assay | IC50=49.6±13.1 μM | 25124282 | ||
| H187 | Growth Inhibition Assay | IC50=12.7±2.7 μM | 25124282 | ||
| H128 | Growth Inhibition Assay | IC50=106.4±9.6 μM | 25124282 | ||
| H69 | Growth Inhibition Assay | IC50=76.9±27.8 μM | 25124282 | ||
| H209 | Growth Inhibition Assay | IC50=258.1±99.8 μM | 25124282 | ||
| DMS153 | Growth Inhibition Assay | IC50=57.8±9.2 μM | 25124282 | ||
| H526 | Growth Inhibition Assay | IC50=7.2±1.7 μM | 25124282 | ||
| DMS114 | Growth Inhibition Assay | IC50=85.8±12.8 μM | 25124282 | ||
| DMS53 | Growth Inhibition Assay | IC50=146.2±36.4 μM | 25124282 | ||
| A2780 | Growth Inhibition Assay | IC50=14.0 ± 1.4 μM | 24209693 | ||
| A2780cisR | Growth Inhibition Assay | IC50=48.9 ± 3.9 μM | 24209693 | ||
| A2780ZD0473R | Growth Inhibition Assay | IC50=64.6 ± 3.2 μM | 24209693 | ||
| SKOV-3 | Growth Inhibition Assay | IC50=43.4 ± 3.9 μM | 24209693 | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | Carboplatin是 CDDP 的衍生物，是一种 DNA 合成抑制剂，在 A2780、SKOV-3、IGROV-1 和 HX62 细胞中可与 DNA 结合，抑制复制和转录，诱导细胞死亡并干扰细胞的修复机制发挥作用 。 它诱导 DNA 链间交联和 DNA-蛋白质交联的形成。在溶液中不稳定，请现配现用！铂类药物不建议用DMSO溶解，易失活！ | |
|---|---|---|
| 特性 | 不建议使用DMSO溶解。[6] | |
| 靶点 |
|
| 体外研究(In Vitro) | ||||
| 体外研究活性 | Carboplatin作用于一组人类卵巢癌细胞系，包括A2780, SKOV3,和 IGROV-1细胞，抑制细胞增殖,IC50分别为6.1 μM, 12.4 μM 和2.2 μM。[1] |
|||
|---|---|---|---|---|
| 细胞实验 | 细胞系 | A2780, SKOV3, IGROV-1 和 HX62 | ||
| 浓度 | 0 到 200 μM | |||
| 孵育时间 | 72 小时 | |||
| 方法 | MTT实验: 指数生长的A2780, SKOV3, IGROV-1和 HX62卵巢癌细胞接种在96孔板中。加入一系列浓度的Carboplatin，再温育72小时。每组实验按一式三份进行。 Sulforhodamine B (SRB)实验:指数生长的 A2780细胞接种在96孔板中。使用浓度不断增加的17-AAG 和Carboplatin处理细胞96小时。使用浓度不断增加的17-AAG或Carboplatin处理细胞 24小时，研究17-AAG 或 Carboplatin处理序列的效果。选中的第一种药剂处理细胞24小时，确保A2780细胞使用第一种药剂至少处理双倍时间(18-24小时)。使用无菌磷酸盐缓冲液冲洗细胞，然后补充培养基。然后，加入第二种药剂 (第一次24小时未处理细胞的)或培养基，再处理96小时。所有实验按一式三份进行。使用中位数效果分析方法按行之有效的原则分析联合研究的效果。使用内部电子表格计算联用的效果。 |
|||
| 实验图片 | 检测方法 | 检测指标 | 实验图片 | PMID |
| Western blot | pChK-2 / Chk-2 p-p53(S15) / p-p53(S46) / p-p53(S392) / p53 p-p38 / p38 / Cleaved PARP / PARP |
|
30049957 | |
| Immunofluorescence | γH2AX |
|
24348048 | |
| Growth inhibition assay | Cell viability |
|
24348048 | |
| 体内研究(In Vivo) | ||
| 体内研究活性 |
Carboplatin (60 mg/kg，通过腹腔注射)单独作用于A2780移植瘤，具有适度的抗肿瘤效果，处理第6天，相对肿瘤体积为8.4，对照组为11.9, 且处理第6天，T/C为67%。[1] |
|
|---|---|---|
| 动物实验 | Animal Models | A2780人类卵巢癌细胞系皮下移植到雌性无胸腺NCr裸鼠(nu/nu)的两侧 |
| Dosages | ≤60 mg/kg （注意：氯化钠溶液与卡铂混合后出现理化、药动学及药效学等方面的配伍禁忌。） | |
| Administration | 腹腔注射 | |
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05846789 | Recruiting | Metastatic Breast Cancer|Triple Negative Breast Cancer|Estrogen-receptor-low Breast Cancer |
Kathy Miller|Genentech Inc.|Indiana University |
January 2024 | Phase 2 |
| NCT06086288 | Not yet recruiting | Merkel Cell Carcinoma |
Fondazione IRCCS Istituto Nazionale dei Tumori Milano |
November 2023 | Phase 2 |
| NCT05856695 | Recruiting | Small Cell Lung Cancer Extensive Stage |
Intergroupe Francophone de Cancerologie Thoracique |
November 17 2023 | Phase 2 |
化学信息&溶解度
| 分子量 | 371.25 | 分子式 | C6H12N2O4Pt |
| CAS号 | 41575-94-4 | SDF | Download Carboplatin SDF |
| Smiles | C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2] | ||
| 储存条件(自收到货起) | 2年 4°C（避光） 粉末 | 此产品性质不稳定，需现配现用!建议您购买分装规格，或者在收到货后进行分装。 | |
|
体外溶解度 |
Water : 4.5 mg/mL Ethanol : Insoluble |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
常见问题及建议解决方法
问题 1:
Can you advise what solvent to use and the concentration for S1215 for in vitro use?
回答：
DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.
